{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Hematopoietic+Cell+Transplant&page=12", "query": { "intervention": "Allogeneic Hematopoietic Cell Transplant", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1002, "total_pages": 101, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Hematopoietic+Cell+Transplant&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Hematopoietic+Cell+Transplant&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T05:29:26.141Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05090384", "title": "Pediatric GVHD Low Risk Steroid Taper Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Graft vs Host Disease", "Allogeneic Bone Marrow Transplantation", "Adverse Effects" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Levine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 50, "start_date": "2022-10-20", "completion_date": "2026-02-25", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 10, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090384" }, { "nct_id": "NCT01998633", "title": "Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophagocytic Lymphohistiocytosis", "Chronic Active Epstein-Barr Virus Infection", "Chronic Granulomatous Disease", "HIGM-1", "Leukocyte Adhesion Deficiency", "IPEX" ], "interventions": [ { "name": "Hematopoietic Stem Cell Transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Months", "maximum_age": "45 Years", "sex": "ALL", "summary": "4 Months to 45 Years" }, "enrollment_count": 47, "start_date": "2013-12", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2022-12-08", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998633" }, { "nct_id": "NCT01534143", "title": "High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "pharmacological study", "type": "OTHER" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1, "start_date": "2012-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534143" }, { "nct_id": "NCT00460421", "title": "A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Palifermin", "type": "DRUG" }, { "name": "Total Body irradiation", "type": "RADIATION" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Swedish Orphan Biovitrum", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "16 Years", "sex": "ALL", "summary": "1 Year to 16 Years" }, "enrollment_count": 27, "start_date": "2006-08", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2014-12-05", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 7, "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00460421" }, { "nct_id": "NCT03007147", "title": "Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 352, "start_date": "2017-08-08", "completion_date": "2034-09-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 184, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03007147" }, { "nct_id": "NCT00003887", "title": "Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "peripheral blood lymphocyte therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": null, "start_date": "1998-08", "completion_date": "2003-02", "has_results": false, "last_update_posted_date": "2011-11-30", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003887" }, { "nct_id": "NCT01929408", "title": "Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)" ], "interventions": [], "intervention_types": [], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 703, "start_date": "2013-07-19", "completion_date": "2018-12-04", "has_results": true, "last_update_posted_date": "2019-11-15", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 12, "location_summary": "Stanford, California • Chicago, Illinois • Baltimore, Maryland + 8 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01929408" }, { "nct_id": "NCT03990051", "title": "Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Ocular Graft-versus-host Disease" ], "interventions": [ { "name": "Pro-ocular™ topical gel", "type": "DRUG" }, { "name": "Placebo topical gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glia, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-10-17", "completion_date": "2021-11-19", "has_results": true, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03990051" }, { "nct_id": "NCT00980655", "title": "Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vaccines, Pneumococcal Conjugate Vaccine" ], "interventions": [ { "name": "13vPnC", "type": "BIOLOGICAL" }, { "name": "23vPS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 251, "start_date": "2010-01-18", "completion_date": "2013-05-16", "has_results": true, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 9, "location_summary": "Lexington, Kentucky • New Hyde Park, New York • New York, New York + 2 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980655" }, { "nct_id": "NCT00741455", "title": "Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2004-06", "completion_date": "2020-05-01", "has_results": true, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-15T05:29:26.141Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00741455" } ] }